Iconic Therapeutics said Wednesday that it has closed $20 million in Series B-1 financing. The investors were MPM Capital, Lundbeckfond Ventures and H.I.G. BioVentures. In conjunction with the funding, Iconic has named MPM partner Dr. William Greene as CEO. Also, MPM’s Todd Foley, H.I.G’s Dr. Bruce Robertson and Dr. Johan Kordel of Lundbeckfond Ventures have been added to Iconic’s board of directors. Based in South San Francisco and Atlanta, Iconic is a biotech firm focused on serious eye disorders.